Bevacizumab for Recurrent Malignant Glioma

NCT00271609 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

88

Enrollment

NIH

Sponsor class

Conditions

Recurrent High-Grade Gliomas
Malignant Gliomas

Interventions

DRUG: Bevacizumab

Sponsor

National Cancer Institute (NCI)